Occupational therapy in spinocerebellar ataxia type 3: An open-label trial

Brazilian Journal of Medical and Biological Research

Volumn 43, Issue 6, 2010, Pages 537-542

  Silva, R C R ^a,b   Saute, J A M ^b   Silva, A C F ^b   Coutinho, A C O ^b   Saraiva Pereira, M L ^a,b   Jardim, L B ^a,b  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

Depression; Machado Joseph disease; Occupational therapy; Polyglutamine diseases; Rehabilitation; Spinocerebellar ataxia 3

Indexed keywords

ATAXIN 3;

ADL DISABILITY; ADULT; ARTICLE; BARTHEL INDEX; CLINICAL ARTICLE; CLINICAL TRIAL; DEPRESSION; FEMALE; FOLLOW UP; FUNCTIONAL INDEPENDENCE MEASURE; HAMILTON SCALE; HUMAN; MALE; OCCUPATIONAL THERAPY; PHYSICAL DISABILITY; QUALITY OF LIFE; SPINOCEREBELLAR DEGENERATION;

EID: 77953952411     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2010005000009     Document Type: Article

References (26)

1. Takiyama Y, Nishizawa M, Tanaka H, Kawashima S, Sakamoto H, Karube Y, et al. The gene for Machado-Joseph disease maps to human chromosome 14q. Nat Genet 1993; 4: 300-304.
2. Kawaguchi Y, Okamoto T, Taniwaki M, Aizawa M, Inoue M, Katayama S, et al. CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1. Nat Genet 1994; 8: 221-228.
3. Bauer PO, Kotliarova SE, Matoska V, Musova Z, Hedvicakova P, Boday A, et al. Fluorescent multiplex PCR - fast method for autosomal dominant spinocerebellar ataxias screening. Genetika 2005; 41: 830-837.
4. Prestes PR, Saraiva-Pereira ML, Silveira I, Sequeiros J, Jardim LB. Machado-Joseph disease enhances genetic fitness: a comparison between affected and unaffected women and between MJD and the general population. Ann Hum Genet 2008; 72: 57-64.
5. Jardim LB, Pereira ML, Silveira I, Ferro A, Sequeiros J, Giugliani R. Machado-Joseph disease in South Brazil: clinical and molecular characterization of kindreds. Acta Neurol Scand 2001; 104: 224-231.
6. Sequeiros J, Coutinho P. Epidemiology and clinical aspects of Machado-Joseph disease. In: Harding A, Deufel T, Chamberlain S (Editors), Hereditary ataxias. Vol. 61. New York: Raven Press; 1993. p 139-153.
7. Kieling C, Prestes PR, Saraiva-Pereira ML, Jardim LB. Survival estimates for patients with Machado-Joseph disease (SCA3). Clin Genet 2007; 72: 543-545.
8. Yamada S, Nishimiya J, Nakajima T, Taketazu F. Linear high intensity area along the medial margin of the internal segment of the globus pallidus in Machado-Joseph disease patients. J Neurol Neurosurg Psychiatry 2005; 76: 573-575.
9. Yuasa T, Ohama E, Harayama H, Yamada M, Kawase Y, Wakabayashi M, et al. Joseph's disease: clinical and pathological studies in a Japanese family. Ann Neurol 1986; 19: 152-157.
10. Durr A, Stevanin G, Cancel G, Duyckaerts C, Abbas N, Didierjean O, et al. Spinocerebellar ataxia 3 and Machado-Joseph disease: clinical, molecular, and neuropathological features. Ann Neurol 1996; 39: 490-499.
11. Iwabuchi K, Tsuchiya K, Uchihara T, Yagishita S. Autosomal dominant spinocerebellar degenerations. Clinical, pathological, and genetic correlations. Rev Neurol 1999; 155: 255-270.
12. Cecchin CR, Pires AP, Rieder CR, Monte TL, Silveira I, Carvalho T, et al. Depressive symptoms in Machado-Joseph disease (SCA3) patients and their relatives. Community Genet 2007; 10: 19-26.
13. Riberto M, Miyazaki MH, Jucá SSH, Sakamoto H, Pinto PPN, Battistella LR. Validação da versão brasileira da medida de independência funcional. Acta Fisiatr 2004; 11: 72-76.
14. Granger CV, Hamilton BB, Keith RA, Zielezny M, Sherwin FS. Advances in functional assessment for rehabilitation. In: Anonymous, Topics in geriatric rehabilitation. Rockville: Aspen; 1986.
15. Mahoney FI, Barthel DW. Functional evaluation: the Barthel index. Md State Med J 1965; 14: 61-65.
16. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-62.
17. Fleck MP, Louzada S, Xavier M, Chachamovich E, Vieira G, Santos L, et al. [Application of the Portuguese version of the abbreviated instrument of quality life WHOQOL-bref]. Rev Saúde Pública 2000; 34: 178-183.
18. Development of the World Health Organization WHOQOLBREF quality of life assessment. The WHOQOL Group. Psychol Med 1998; 28: 551-558.
19. Kieling C, Rieder C, Silva ACF, Saute JA, Cecchin CR, Monte TL, et al. A neurological examination score for the assessment of spinocerebellar ataxia 3 (SCA3). Eur J Neurol 2008; 15: 371-376.
20. Schmitz-Hubsch T, du Montcel ST, Baliko L, Berciano J, Boesch S, Depondt C, et al. Scale for the assessment and rating of ataxia: development of a new clinical scale. Neurology 2006; 66: 1717-1720.
21. Foster M. Theoretical frameworks. In: Turner A, Foster M, Johnson S (Editors), Occupational therapy and physical dysfunction. 5th edn. Amsterdam: Elsevier; 2002.
22. Martins S, Coutinho P, Silveira I, Giunti P, Jardim LB, Calafell F, et al. Cis-acting factors promoting the CAG intergenerational instability in Machado-Joseph disease. Am J Med Genet B Neuropsychiatr Genet 2008; 147B: 439-446.
23. Perez-Avila I, Fernandez-Vieitez JA, Martinez-Gongora E, Ochoa-Mastrapa R, Velazquez-Manresa MG. [Effects of a physical training program on quantitative neurological indices in mild stage type 2 spinocerebellar ataxia patients]. Rev Neurol 2004; 39: 907-910.
24. Paneque HM, Reynaldo AR, Velazquez PL, Santos FN, Miranda HE, Real PN, et al. [Type 2 spinocerebellar ataxia: an experience in psychological rehabilitation]. Rev Neurol 2001; 33: 1001-1005.
25. Rub U, Seidel K, Ozerden I, Gierga K, Brunt ER, Schols L, et al. Consistent affection of the central somatosensory system in spinocerebellar ataxia type 2 and type 3 and its significance for clinical symptoms and rehabilitative therapy. Brain Res Rev 2007; 53: 235-249.
26. Monte TL, Rieder CR, Tort AB, Rockenback I, Pereira ML, Silveira I, et al. Use of fluoxetine for treatment of Machado-Joseph disease: an open-label study. Acta Neurol Scand 2003; 107: 207-210.